PMID- 36756105
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230210
IS  - 2278-330X (Print)
IS  - 2278-4306 (Electronic)
IS  - 2278-330X (Linking)
VI  - 11
IP  - 4
DP  - 2022 Oct
TI  - Indian Data on HER2 Fluorescence In Situ Hybridization in Invasive Breast Cancer 
      with Immunohistochemically Equivocal Results As Per 2018 ASCO/CAP Guidelines.
PG  - 281-286
LID - 10.1055/s-0042-1751052 [doi]
AB  - Biren ParikhIntroduction  Hormonal status and HER2 expression are valuable 
      biomarkers and dictate the management of the patients diagnosed with invasive 
      breast cancer (IBC). It is crucial to identify the patients who truly respond to 
      anti-HER2 targeted therapy. Updated 2018 American Society of Clinical Oncology 
      (ASCO)/College of American Pathologists (CAP) guidelines has recommended certain 
      modifications in HER2 interpretation by fluorescence in situ hybridization (FISH) 
      with concomitant immunohistochemistry (IHC). Objectives  We aimed to evaluate 
      HER2 FISH interpretation in IBC with equivocal IHC results as per 2018 ASCO/CAP 
      recommendations and compare FISH results with hormonal receptor status. Materials 
      and Methods  FISH results of 502 cases of IBC with equivocal IHC report between 
      January 2016 to January 2022 were reviewed retrospectively. FISH results were 
      categorized according to ASCO/CAP guidelines 2018 into five respective groups. 
      Results  FISH testing in IHC equivocal cases showed 219 (43.6%) cases were 
      classic amplified (positive) belonged to group 1, 217(43.2%) cases were classic 
      nonamplified (negative) fell into group 5, 39 (7.8%) and 02 (0.4%) patients were 
      in group 2 (negative) and group 3 (positive), and 25 (5.0%) cases were in group 4 
      (negative). About 52.1 and 49.3% of cases with estrogen receptor and progesterone 
      receptor positivity were reported as HER2 positive. Among 502 cases, 25 equivocal 
      cases according to the 2013 guidelines were redefined as HER2 negative and 02 
      (0.4%) cases reported positive were classified negative as per updated 2018 
      guidelines. Conclusion  Revised 2018 guidelines is helpful in accurate 
      identification of HER2 status and in avoiding targeted therapy in unwarranted 
      cases. Updated 2018 guidelines has removed equivocal HER2-FISH category that has 
      eliminated management dilemma in these cases. Only long-term clinical follow-up 
      will establish the validity of the updated guidelines.
CI  - MedIntel Services Pvt Ltd. This is an open access article published by Thieme 
      under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial 
      License, permitting copying and reproduction so long as the original work is 
      given appropriate credit. Contents may not be used for commercial purposes, or 
      adapted, remixed, transformed or built upon. ( 
      https://creativecommons.org/licenses/by-nc-nd/4.0/ ).
FAU - Nagarjun, B R
AU  - Nagarjun BR
AD  - Department of Oncopathology, Gujarat Cancer and Research Institute, Ahmedabad, 
      Gujarat, India.
FAU - Parikh, Biren
AU  - Parikh B
AD  - Department of Oncopathology, Gujarat Cancer and Research Institute, Ahmedabad, 
      Gujarat, India.
FAU - Patel, Manaswi Nareshkumar
AU  - Patel MN
AD  - Former Fellow in Oncopathology, Gujarat Cancer and Research Institute, Ahmedabad, 
      Gujarat, India.
FAU - Trivedi, Pina J
AU  - Trivedi PJ
AD  - Department of Cytogenetics, Gujarat Cancer and Research Institute, Ahmedabad, 
      Gujarat, India.
FAU - Patel, Dharmesh M
AU  - Patel DM
AD  - Department of Cytogenetics, Gujarat Cancer and Research Institute, Ahmedabad, 
      Gujarat, India.
LA  - eng
PT  - Journal Article
DEP - 20220823
PL  - India
TA  - South Asian J Cancer
JT  - South Asian journal of cancer
JID - 101618774
PMC - PMC9902087
OTO - NOTNLM
OT  - ASCO/CAP guidelines 2018
OT  - FISH
OT  - HER2
OT  - equivocal
OT  - invasive breast cancer
COIS- Conflict of Interest None declared.
EDAT- 2023/02/10 06:00
MHDA- 2023/02/10 06:01
PMCR- 2022/08/01
CRDT- 2023/02/09 02:22
PHST- 2023/02/09 02:22 [entrez]
PHST- 2023/02/10 06:00 [pubmed]
PHST- 2023/02/10 06:01 [medline]
PHST- 2022/08/01 00:00 [pmc-release]
AID - 2210759 [pii]
AID - 10.1055/s-0042-1751052 [doi]
PST - epublish
SO  - South Asian J Cancer. 2022 Aug 23;11(4):281-286. doi: 10.1055/s-0042-1751052. 
      eCollection 2022 Oct.